Circulating CD34+ Cell Count is Associated with Extent of Subclinical Atherosclerosis in Asymptomatic Amish Men, Independent of 10-Year Framingham Risk.
BACKGROUND
Bone-marrow derived progenitor cells (PCs) may play a role in maintaining vascular health by actively repairing damaged endothelium. The purpose of this study in asymptomatic Old Order Amish men (n = 90) without hypertension or diabetes was to determine if PC count, as determined by CD34+ cell count in peripheral blood, was associated with 10-year risk of cardiovascular disease (CVD) and measures of subclinical atherosclerosis.


RESULTS
CD34+ cell count by fluorescence-activated cell sorting, coronary artery calcification (CAC) by electron beam computed tomography, and CVD risk factors were obtained. Carotid intimal-medial thickness (CIMT) also was obtained in a subset of 57 men. After adjusting for 10-year CVD risk, CD34+ cell count was significantly associated with CAC quantity (p = 0.03) and CIMT (p < 0.0001). A 1-unit increase in natural-log transformed CD34+ cell count was associated with an estimated 55.2% decrease (95% CI: -77.8% to -9.3%) in CAC quantity and an estimated 14.3% decrease (95% CI: -20.1% to -8.1%) in CIMT.


CONCLUSIONS
Increased CD34+ cell count was associated with a decrease in extent of subclinical atherosclerosis in multiple arterial beds, independent of 10-year CVD risk. Further investigations of associations of CD34+ cell count with subclinical atherosclerosis in asymptomatic individuals could provide mechanistic insights into the atherosclerotic process.
Bielak
Lawrence F
LF
Department of Epidemiology, University of Michigan, Ann Arbor, Michigan.
Horenstein
Richard B
RB
Ryan
Kathleen A
KA
Sheedy
Patrick F
PF
Rumberger
John A
JA
Tanner
Keith
K
Post
Wendy
W
Mitchell
Braxton D
BD
Shuldiner
Alan R
AR
Peyser
Patricia A
PA
J Am Coll Cardiol. 2006 Dec 19;48(12):2553-60
17174197
Circ Res. 2001 Jul 6;89(1):E1-7
11440984
N Engl J Med. 2008 Mar 27;358(13):1336-45
18367736
N Engl J Med. 2005 Sep 8;353(10):999-1007
16148285
J Clin Pharmacol. 2004 Aug;44(8):881-9
15286092
Clin Chem. 1972 Jun;18(6):499-502
4337382
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
2407762
Int Heart J. 2006 Jan;47(1):95-105
16479045
Atherosclerosis. 2008 Apr;197(2):496-503
18249408
Circulation. 2004 Jan 20;109(2):220-6
14691039
Nature. 1993 Apr 29;362(6423):801-9
8479518
N Engl J Med. 2003 Feb 13;348(7):593-600
12584367
Circulation. 2008 Feb 12;117(6):743-53
18212285
Circ Res. 2007 Apr 27;100(8):1116-27
17463327
Stroke. 1997 Nov;28(11):2195-200
9368564
Circulation. 2005 Jun 7;111(22):2981-7
15927972
Am Heart J. 2008 May;155(5):823-8
18440328
J Am Coll Cardiol. 2005 May 3;45(9):1441-8
15862416
Am Heart J. 2006 Jul;152(1):190-5
16824855
Atherosclerosis. 2008 Feb;196(2):888-95
17368463
J Am Coll Cardiol. 2008 May 6;51(18):1760-71
18452782
Circulation. 2003 Jul 29;108(4):457-63
12860902
Stroke. 2006 Sep;37(9):2277-82
16873710
Am J Epidemiol. 1997 Sep 15;146(6):483-94
9290509
Circulation. 2001 Jul 24;104(4):412-7
11468202
J Am Coll Cardiol. 2005 Jul 5;46(1):158-65
15992651